141
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes

      research-article
      1 , 2 , 3 , 4 , 5 , 6 , 1 , 7 , 8 , 9 , 4 , 1 , 1 , 1 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 14 , 14 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 15 , 25 , 4 , FORGE Canada Consortium, 27 , 28 , 5 , 3 , 10 , 4 , 9 , 1 , 29 , 30
      Nature genetics

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Megalencephaly-capillary malformation (MCAP) and megalencephaly-polymicrogyria-polydactyly-hydrocephalus (MPPH) syndromes are sporadic overgrowth disorders associated with markedly enlarged brain size and other recognizable features 1- 5 . We performed exome sequencing in three families with MCAP or MPPH and confirmed our initial observations in exomes from 7 MCAP and 174 control individuals, as well as in 40 additional megalencephaly subjects using a combination of Sanger sequencing, restriction-enzyme assays, and targeted deep sequencing. We identified de novo germline or postzygotic mutations in three core components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway. These include two mutations of AKT3, one recurrent mutation of PIK3R2 in 11 unrelated MPPH families, and 15 mostly postzygotic mutations of PIK3CA in 23 MCAP and one MPPH patients. Our data highlight the central role of PI3K/AKT signaling in vascular, limb and brain development, and emphasize the power of massively parallel sequencing in a challenging context of phenotypic and genetic heterogeneity combined with postzygotic mosaicism.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations

          Evidence for the etiology of autism spectrum disorders (ASD) has consistently pointed to a strong genetic component complicated by substantial locus heterogeneity 1,2 . We sequenced the exomes of 20 sporadic cases of ASD and their parents, reasoning that these families would be enriched for de novo mutations of major effect. We identified 21 de novo mutations, of which 11 were protein-altering. Protein-altering mutations were significantly enriched for changes at highly conserved residues. We identified potentially causative de novo events in 4/20 probands, particularly among more severely affected individuals, in FOXP1, GRIN2B, SCN1A, and LAMC3. In the FOXP1 mutation carrier, we also observed a rare inherited CNTNAP2 mutation and provide functional support for a multihit model for disease risk 3 . Our results demonstrate that trio-based exome sequencing is a powerful approach for identifying novel candidate genes for ASD and suggest that de novo mutations may contribute substantially to the genetic risk for ASD.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Akt signalling in health and disease.

            Akt (also known as protein kinase B or PKB) comprises three closely related isoforms Akt1, Akt2 and Akt3 (or PKBα/β/γ respectively). We have a very good understanding of the mechanisms by which Akt isoforms are activated by growth factors and other extracellular stimuli as well as by oncogenic mutations in key upstream regulatory proteins including Ras, PI3-kinase subunits and PTEN. There are also an ever increasing number of Akt substrates being identified that play a role in the regulation of the diverse array of biological effects of activated Akt; this includes the regulation of cell proliferation, survival and metabolism. Dysregulation of Akt leads to diseases of major unmet medical need such as cancer, diabetes, cardiovascular and neurological diseases. As a result there has been substantial investment in the development of small molecular Akt inhibitors that act competitively with ATP or phospholipid binding, or allosterically. In this review we will briefly discuss our current understanding of how Akt isoforms are regulated, the substrate proteins they phosphorylate and how this integrates with the role of Akt in disease. We will furthermore discuss the types of Akt inhibitors that have been developed and are in clinical trials for human cancer, as well as speculate on potential on-target toxicities, such as disturbances of heart and vascular function, metabolism, memory and mood, which should be monitored very carefully during clinical trial. Copyright © 2011 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              High-throughput oncogene mutation profiling in human cancer.

              Systematic efforts are underway to decipher the genetic changes associated with tumor initiation and progression. However, widespread clinical application of this information is hampered by an inability to identify critical genetic events across the spectrum of human tumors with adequate sensitivity and scalability. Here, we have adapted high-throughput genotyping to query 238 known oncogene mutations across 1,000 human tumor samples. This approach established robust mutation distributions spanning 17 cancer types. Of 17 oncogenes analyzed, we found 14 to be mutated at least once, and 298 (30%) samples carried at least one mutation. Moreover, we identified previously unrecognized oncogene mutations in several tumor types and observed an unexpectedly high number of co-occurring mutations. These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention.
                Bookmark

                Author and article information

                Journal
                9216904
                2419
                Nat Genet
                Nat. Genet.
                Nature genetics
                1061-4036
                1546-1718
                13 June 2012
                24 June 2012
                01 February 2013
                : 44
                : 8
                : 934-940
                Affiliations
                [1 ]Center for Integrative Brain Research, Seattle Children’s Hospital, Seattle, WA
                [2 ]Department of Human Genetics, University of Chicago, Chicago, IL
                [3 ]Department of Genome Sciences, University of Washington, Seattle, WA
                [4 ]Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada
                [5 ]Genome Damage & Stability Centre, University of Sussex, Falmer, Brighton, United Kingdom
                [6 ]Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI
                [7 ]Genome Quebec Innovation Centre, McGill University, Montreal, QC, Canada
                [8 ]Division of Medical Genetics, A. I. duPont Hospital for Children, Wilmington, DE
                [9 ]Department of Genetics, Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada
                [10 ]Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, CA
                [11 ]Department of Human Genetics, University Hospital Essen, Essen, Germany
                [12 ]Department of Paediatrics, Queen’s University, Kingston, ON, Canada
                [13 ]Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada
                [14 ]Department of Medical Genetics, University of Calgary, Calgary, AB, Canada
                [15 ]Division of Clinical and Metabolic Genetics, Hospital for Sick Children, Toronto, ON, Canada
                [16 ]Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI
                [17 ]Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI
                [18 ]Department of Medical Genetics, MassGeneral Hospital for Children, Boston, MA
                [19 ]Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
                [20 ]Department of Genetics, North York General Hospital, Toronto, ON, Canada
                [21 ]Providence Child Neurology, Providence Sacred Heart Medical Center and Children’s Hospital, Spokane, WA
                [22 ]Clinical Genetics Department, St George’s Hospital, University of London, London, United Kingdom
                [23 ]Pediatric Neurology Unit, Wolfson Medical Center, Holon, Israel
                [24 ]Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
                [25 ]Department of Neuropediatrics, University of Goettingen, Goettingen, Germany
                [27 ]Department of Human Genetics, McGill University, Montreal, QC, Canada
                [28 ]Ottawa Hospital Research Institute, University of Ottawa, ON, Canada
                [29 ]Department of Pediatrics, University of Washington, Seattle, WA
                [30 ]Department of Neurology, University of Washington, Seattle, WA
                Author notes
                Corresponding author: William B. Dobyns, M.D., Seattle Children’s Research Institute, Center for Integrative Brain Research, 1900 Ninth Avenue, M/S C9S-10, Seattle WA 98101, USA, Phone: 1-206-884-2972, Fax: 1-206- 206-884-1210, wbd@ 123456uw.edu
                [26]

                Membership of the Steering committee is provided in the Supplementary Note

                Article
                NIHMS382270
                10.1038/ng.2331
                3408813
                22729224
                940c3478-f772-4875-b9db-4f2ba86ae87f

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Institute of General Medical Sciences : NIGMS
                Award ID: T32 GM008243 || GM
                Categories
                Article

                Genetics
                Genetics

                Comments

                Comment on this article